SeraCare Life Sciences (SRLS) Misses Q3 EPS by 4c; CEO Departs

SeraCare Life Sciences (NASDAQ: SRLS) reported Q3 EPS of $0.03, $0.04 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $11 million versus the consensus estimate of $11.82 million.

SeraCare also announced the following leadership changes.

• Susan Vogt, previously CEO of SeraCare, is no longer with the Company. She guided SeraCare during the past five years and led a reorganization, a return to profitability and improved operations.
  
  
• Greg Gould has been named interim CEO and continues in his role as CFO.
  
  
• The Board has started a search for a new CEO. Healthcare industry veteran and Chairman of the Board Joseph Nemmers will work closely with management during the transition period.
  
  
• The head of business development is no longer with the Company. The Board is continuing its review of the Company's current business development processes and expects to make appropriate changes to improve performance.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Faeth Therapeutics names two SVPs ahead of clinical milestones
• Stardust Power (SDST) Tops Q2 EPS by 1c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c